Zsofia K Stadler

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome.
    Erin E Salo Mullen
    Fam Cancer . 2017
  2. doi request reprint Diagnosis and management of DNA mismatch repair-deficient colorectal cancer
    Zsofia K Stadler
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Electronic address
    Hematol Oncol Clin North Am 29:29-41. 2015
  3. doi request reprint Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
  4. doi request reprint Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
  5. pmc Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
  6. pmc Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
    Zsofia K Stadler
    Zsofia K Stadler, Francesca Battaglin, Sumit Middha, Jaclyn F Hechtman, Christina Tran, Andrea Cercek, Rona Yaeger, Neil H Segal, Anna M Varghese, Diane L Reidy Lagunes, Nancy E Kemeny, Erin E Salo Mullen, Asad Ashraf, Martin R Weiser, Julio Garcia Aguilar, Mark E Robson, Kenneth Offit, Maria E Arcila, Michael F Berger, Jinru Shia, David B Solit, and Leonard B Saltz, Memorial Sloan Kettering Cancer Center, New York, NY and Francesca Battaglin, Veneto Institute of Oncology, Padua, Italy
    J Clin Oncol 34:2141-7. 2016
  7. pmc An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
  8. doi request reprint The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Colorectal Cancer 11:304-8. 2012
  9. doi request reprint Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
  10. doi request reprint Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min
    Andrea Cercek
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Oncol Pract 12:e548-53. 2016

Collaborators

Detail Information

Publications35

  1. doi request reprint Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome.
    Erin E Salo Mullen
    Fam Cancer . 2017
    ....
  2. doi request reprint Diagnosis and management of DNA mismatch repair-deficient colorectal cancer
    Zsofia K Stadler
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Electronic address
    Hematol Oncol Clin North Am 29:29-41. 2015
    ..Oncologists remain at the forefront of diagnosing, treating, and managing patients with MMR-D/MSI-H CRC and ensuring that the clinical care of these patients reflect our evolving understanding of this unique CRC subtype. ..
  3. doi request reprint Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
    ..Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown...
  4. doi request reprint Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
    ..Breast-pancreas cancer families with BRCA1 mutations have also been observed. The influence of a family history (FH) of PC on BRCA mutation prevalence in patients with breast cancer (BC) is unknown...
  5. pmc Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
    ..To date, however, the clinical utility of GWAS-derived risk markers remains limited...
  6. pmc Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
    Zsofia K Stadler
    Zsofia K Stadler, Francesca Battaglin, Sumit Middha, Jaclyn F Hechtman, Christina Tran, Andrea Cercek, Rona Yaeger, Neil H Segal, Anna M Varghese, Diane L Reidy Lagunes, Nancy E Kemeny, Erin E Salo Mullen, Asad Ashraf, Martin R Weiser, Julio Garcia Aguilar, Mark E Robson, Kenneth Offit, Maria E Arcila, Michael F Berger, Jinru Shia, David B Solit, and Leonard B Saltz, Memorial Sloan Kettering Cancer Center, New York, NY and Francesca Battaglin, Veneto Institute of Oncology, Padua, Italy
    J Clin Oncol 34:2141-7. 2016
    ....
  7. pmc An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
    ....
  8. doi request reprint The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Colorectal Cancer 11:304-8. 2012
    ..The purpose of this study was to report the prevalence of TC and benign thyroid disease in patients with FAP...
  9. doi request reprint Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
    ..Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim...
  10. doi request reprint Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min
    Andrea Cercek
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Oncol Pract 12:e548-53. 2016
    ..Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly...
  11. doi request reprint Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome
    Erin E Salo-Mullen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 295, New York, NY, 10065, USA
    Fam Cancer 13:459-67. 2014
    ..We highlight the need for recognition and awareness of mosaicism as it may provide an explanation for variable phenotypic presentations and may alter the genetic counseling risk assessment of affected individuals and family members. ..
  12. doi request reprint BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
    ..Analysis of a tumor specimen indicates loss of heterozygosity. These results support the conclusion that BRCA1 331G > A (R71K) is a deleterious mutation...
  13. doi request reprint Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply?
    Clare D'Arcy
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 35:1743-8. 2011
    ....
  14. pmc CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site
    Zarina Yelskaya
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 11:e0165654. 2016
    ..These results support the conclusion that CDH1 c.1679C>G (p.T560R) variant is a pathogenic mutation and contributes to HDGC through disruption of normal splicing...
  15. pmc Clinical and genetic determinants of ovarian metastases from colorectal cancer
    Karuna Ganesh
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer . 2016
    ..To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and optimal clinical management remains unclear...
  16. ncbi request reprint Genome-wide association studies of cancer: principles and potential utility
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:629-37. 2010
    ....
  17. doi request reprint Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 214:61-7. 2012
    ..Our study describes the impact of routine immunohistochemistry (IHC) analysis of tumor tissue for loss of MMR protein expression in early age-of-onset CRC patients undergoing resection...
  18. pmc Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol . 2016
    ..Modern Pathology advance online publication, 16 December 2016; doi:10.1038/modpathol.2016.198...
  19. ncbi request reprint Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients
    Vivian E Strong
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Gastroenterology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Ann Surg . 2016
    ..The aim of this study was to describe postoperative outcomes of total gastrectomy at our institution for patients with hereditary diffuse gastric cancer (HDGC)...
  20. pmc Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches
    Ibrahim H Sahin
    a Department of Medicine, Icahn School of Medicine at Mount Sinai St Luke s Roosevelt Hospital Center, New York, NY, USA
    Expert Rev Gastroenterol Hepatol 10:893-905. 2016
    ..In this review we discuss the characteristics of genomic instability in pancreatic cancer along with its clinical implications and the utility of DNA targeting agents particularly PARP inhibitors as a novel treatment approach. ..
  21. doi request reprint Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA
    Fam Cancer 14:61-8. 2015
    ....
  22. pmc Identification of germline genetic mutations in patients with pancreatic cancer
    Erin E Salo-Mullen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York
    Cancer 121:4382-8. 2015
    ..In the current study, the authors sought to determine mutation prevalence and characteristics that are predictive of an inherited predisposition for PAC...
  23. pmc Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
    Lik Hang Lee
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 29:1433-1442. 2016
    ....
  24. doi request reprint Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...
  25. doi request reprint Genome-wide association studies of cancer predisposition
    Zsofia K Stadler
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hematol Oncol Clin North Am 24:973-96. 2010
    ..Studies involving more heterogeneous populations, determination of the causal variants, and functional studies are now necessary to further elucidate the potential biologic and clinical significance of the observed associations...
  26. ncbi request reprint False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer
    Anya Litvak
    From the Gastrointestinal Oncology Service, Department of Medicine, Department of Surgery, and Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 12:907-13. 2014
    ..False-positive results greater than 15 ng/mL are rare, and all confirmed CEA levels greater than 35 ng/mL were associated with cancer recurrence...
  27. ncbi request reprint Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer
    Andrea Cercek
    From the aGastrointestinal Oncology Service, Department of Medicine, bDepartment of Radiation Therapy, and cColorectal Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 12:513-9. 2014
    ..FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients. ..
  28. pmc Rare de novo germline copy-number variation in testicular cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Hum Genet 91:379-83. 2012
    ....
  29. ncbi request reprint Genetic testing in gastrointestinal cancers: a case-based approach
    Kasmintan Schrader
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 26:433-6, 438, 444-6 passim. 2012
    ..In this article, we use a case-based approach to focus on the hereditary aspects of the most common GI cancers, including pancreatic, gastric, and colon cancer...
  30. doi request reprint Diagnosing hereditary colorectal cancer
    David J Gallagher
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 9:205-11. 2010
    ..While these associations have helped to identify potentially important pathways in CRC carcinogenesis, at the current time, the clinical use of such genetic risk variants in colon cancer risk stratification remains limited...
  31. doi request reprint Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
    Catherine A Shu
    Division of Hematology Oncology, Columbia University Medical Center, New York, New York
    JAMA Oncol 2:1434-1440. 2016
    ..Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial...
  32. ncbi request reprint A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer
    Joseph Vijai
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Discov 6:1267-1275. 2016
    ..53, ORER+ = 1.73), particularly for the estrogen receptor-positive subset (P < 0.007)...
  33. pmc Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group
    Marina J Corines
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 295, New York, NY, 10065, USA
    J Genet Couns . 2016
    ..Following genetic counseling, a need exists for ongoing educational and emotional support in LS. Implementation of resources such as the LSEW and LSPAN is feasible and perceived as helpful by participants...
  34. ncbi request reprint Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family
    Ciyu Yang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Breast Cancer Res Treat 160:447-456. 2016
    ..Mutations in PALB2 have been associated with a predisposition to breast and pancreatic cancers. This study aims to characterize a novel PALB2 exon 13 duplication in a hereditary breast and ovarian cancer family...
  35. doi request reprint Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 33:1639-45. 2009
    ..Such a cost-effective approach carries significant implication, as immunohistochemistry is being widely used as first-line screening for HNPCC...